• A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice
• A model for the dynamics of expanded CAG repeat alleles: <em>ATXN2</em> and <em>ATXN3</em> as prototypes
• A pilot study: handgrip as a predictor in the disease progression of SCA3
• An NMR Toolkit to Probe Amyloid Oligomer Inhibition in Neurodegenerative Diseases: From Ligand Screening to Dissecting Binding Topology and Mechanisms of Action
• Antisense Oligonucleotide Silencing Reverses Abnormal Neurochemistry in Spinocerebellar Ataxia 3 Mice
• ASO silencing reverses abnormal neurochemistry in spinocerebellar ataxia 3 mice
• ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
• Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics
• Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease
• Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3
• Caffeine Consumption and Interaction with ADORA2A, CYP1A2 and NOS1 Variants Do Not Influence Age at Onset of Machado-Joseph Disease
• Case report: Short-term efficacy and changes in ¹⁸F-FDG-PET with acute multi-target stimulation in spinocerebellar ataxia type 3 (SCA3/MJD)
• Cell-Free and In Vivo Characterization of the Inhibitory Activity of <em>Lavado</em> Cocoa Flavanols on the Amyloid Protein Ataxin-3: Toward New Approaches against Spinocerebellar Ataxia Type 3
• Cognitive-affective manifestations since premanifest phases of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease
• Compressed cerebellar functional connectome hierarchy in spinocerebellar ataxia type 3
• Correction to: The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factors
• Correction to: The frequency of non‑motor symptoms in SCA3 and their association with disease severity and lifestyle factors
• Cross talk about the role of Neuropeptide Y in CNS disorders and diseases
• Disrupted cerebellar structural connectome in spinocerebellar ataxia type 3 and its association with transcriptional profiles
• Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation
• Endosome mediated nucleocytoplasmic trafficking and endomembrane allocation is crucial to polyglutamine toxicity
• Establishment of human-induced pluripotent stem cell GZHMCi0011-A from peripheral blood mononuclear cells from a volunteer with 14/63 CAG repeats of the ATXN3 mutation
• Exploring functional and structural connectivity disruptions in spinocerebellar ataxia type 3: Insights from gradient analysis
• Factors Influencing Health-Related Quality of Life of Patients with Spinocerebellar Ataxia
• Feasibility and impact of a physical activity and lifestyle program for Aboriginal families with Machado-Joseph disease in the Top End of Australia
• Functional impact of bilateral vestibular loss and the unexplained complaint of oscillopsia
• Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3
• Genetic Ablation of Inositol 1,4,5-Trisphosphate Receptor Type 2 (IP₃R2) Fails to Modify Disease Progression in a Mouse Model of Spinocerebellar Ataxia Type 3
• Genetic Epidemiology and Clinical Characteristics of Patients with Spinocerebellar Ataxias in an Unexplored Brazilian State, Using Strategies for Resource-Limited Settings
• Genetic screening for Huntington disease phenocopies in Sweden: A tertiary center case series focused on short tandem repeat (STR) disorders
• Global DNA methylation is not elevated in blood samples from Machado-Joseph disease mutation carriers
• Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of spinocerebellar ataxia type 3
• Graft-derived neurons and bystander effects are maintained for six months after human iPSC-derived NESC transplantation in mice's cerebella
• IL-4/STAT6 axis observed to reverse proliferative defect in SCA3 patient-derived neural progenitor cells
• Imbalanced optimal feedback motor control system in spinocerebellar ataxia type 3
• Implications of specific lysine residues within ataxin-3 for the molecular pathogenesis of Machado-Joseph disease
• Improvement of spinocerebellar ataxia 3 symptoms treated with Eurythmy Therapy - A Case Vignette
• Improvement of Spinocerebellar Ataxia 3 Symptoms Treated with Eurythmy Therapy: A Case Vignette
• In Memoriam: Paula Coutinho (1941-2022), a pioneer in Neurogenetics
• Insight into the early pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3/machado-joseph disease from mouse models
• Investigating the therapeutic effects of novel compounds targeting inflammatory IL-1β and IL-6 signaling pathways in spinocerebellar ataxia type 3
• Islands and Neurology: An Exploration into a Unique Association
• Lingual Fasciculation as a Point of Call for the Diagnosis of Amyotrophic Lateral Sclerosis: A Literature Review
• Lysine 117 on ataxin-3 modulates toxicity in <em>Drosophila</em> models of Spinocerebellar Ataxia Type 3
• Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3
• Machado-Joseph disease in a Sudanese family links East Africa to Portuguese families and allows reestimation of ancestral age of the Machado lineage
• Mitochondrial Dysfunction and Decreased Cytochrome <em>c</em> in Cell and Animal Models of Machado-Joseph Disease
• Modification of Huntington's disease by short tandem repeats
• Molecular Imaging in CANVAS: A Contribution for Differential Diagnosis?
• O-GlcNAcylation and Its Roles in Neurodegenerative Diseases
• Pharmacological inhibition of acetylcholinesterase improves the locomotion defective phenotype of a SCA3 <em>C. elegans</em> model
• PolyQ-Expansion Causes Mitochondria Fragmentation Independent of Huntingtin and Is Distinct from Traumatic Brain Injury (TBI)/Mechanical Stress-Mediated Fragmentation Which Results from Cell Death
• Preconditioning of exosomes derived from human olfactory ensheathing cells improved motor coordination and balance in an SCA3/MJD mouse model: A new therapeutic approach
• Preimplantation Genetic Testing of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease-Robust Tools for Direct and Indirect Detection of the ATXN3 (CAG)(n) Repeat Expansion
• Prevalence of repeat expansions causing autosomal dominant spinocerebellar ataxias in Hokkaido, the northernmost island of Japan
• Production of Spinocerebellar Ataxia Type 3 Model Mice by Intravenous Injection of AAV-PHP.B Vectors
• Progression of Retinal Ganglion Cell and Nerve Fiber Layer Loss in Spinocerebellar Ataxia 3 Patients
• Randomized double-blind placebo-controlled trial of the effects of oral trehalose in spinocerebellar ataxia type 3: An interim analysis
• Regional and age-dependent changes in ubiquitination in cellular and mouse models of spinocerebellar ataxia type 3
• Roles of the cerebellum and basal ganglia in temporal integration: Insights from a synchronized tapping task
• Single-Session Cerebellar Transcranial Direct Current Stimulation Improves Postural Stability and Reduces Ataxia Symptoms in Spinocerebellar Ataxia
• Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment
• Spermidine treatment: induction of autophagy but also apoptosis?
• Spinocerebellar Ataxia Type 3 Pathophysiology-Implications for Translational Research and Clinical Studies
• Spinocerebellar ataxia type 4 is not detected in a cohort from Hokkaido, the northernmost island of Japan
• Spinocerebellar Ataxias: Phenotypic Spectrum of PolyQ versus Non-Repeat Expansion Forms
• Stage-dependent biomarker changes in spinocerebellar ataxia type 3
• Stage-Dependent Biomarker Changes in Spinocerebellar Ataxia Type 3
• T2-hyperintensity in the internal globus pallidus in Machado-Joseph disease
• Temporal Relationship between Impairment of Cerebellar Motor Learning and Deterioration of Ataxia in Patients with Cerebellar Degeneration
• The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases
• THE HIDDEN VESTIBULAR FEATURES OF MACHADO JOSEPH DISEASE (SPINOCEREBELLAR ATAXIA 3)
• The longitudinal progression of MRI changes in pre-ataxic carriers of SCA3/MJD
• The natural breakthrough: phytochemicals as potent therapeutic agents against spinocerebellar ataxia type 3
• The overarching effects of vestibular deficit: Imbalance, anxiety, and spatial disorientation
• The parkin V380L variant is a genetic modifier of Machado-Joseph disease with impact on mitophagy
• The vestibular symptomatology of Machado-Joseph Disease
• Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3
• Tissue-Specific Vulnerability to Apoptosis in Machado-Joseph Disease
• Towards Understanding Neurodegenerative Diseases: Insights from <em>Caenorhabditis elegans</em>
• Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3
• Trehalose prevents the formation of aggregates of mutant ataxin-3 and reduces soluble ataxin-3 protein levels in an SCA3 cell model
• Viral-based animal models in polyglutamine disorders